NEW YORK (GenomeWeb News) – SRI International and Spyglass Technologies today announced an exclusive licensing deal to commercialize SRI's underwater mass spectrometry technology.

The agreement calls for St. Petersburg, Fla.-based Spyglass to apply SRI's in situ membrane introduction mass spec (MIMS) technology to "a broad range of commercial, research, and government applications." Additionally, Spyglass will bundle the MIMS device with other underwater sensors, and the partners will continue collaborating on applications of the technology for other markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.